Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Stocks · News reference
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28
JP Morgan Maintains Overweight on Braze, Lowers Price Target to $34
JP Morgan analyst Alexei Gogolev maintains Braze (NASDAQ:BRZE) with a Overweight and lowers the price target from $35 to $34.
Canaccord Genuity Maintains Buy on Braze, Raises Price Target to $37
Canaccord Genuity analyst David Hynes maintains Braze (NASDAQ:BRZE) with a Buy and raises the price target from $35 to $37.
Raymond James Maintains Outperform on Braze, Raises Price Target to $33
Raymond James analyst Brian Peterson maintains Braze (NASDAQ:BRZE) with a Outperform and raises the price target from $27 to $33.